TickerFacts.

Company research / BVS

Bioventus Inc. (BVS)

Build a valuation ↗↓ Download CSV

CIK 0001665988 · Nasdaq · Surgical & Medical Instruments & Apparatus

  • Sector Manufacturing
  • Incorporated DE
  • Fiscal year ends Dec 31

For the year ended 2025-12-31, Bioventus Inc. reported revenue of $568.09M. Revenue fell 0.9% from the prior annual period. Over the twelve months to 2026-06-27, revenue was $581.85M.

Key ratios (year ended 2025-12-31)

68.3%
Gross margin
9.5%
Operating margin
4.0%
Net margin
12.3%
Return on year-end equity
-0.9%
Revenue growth (YoY)

Beyond the statements

Follow the company.

Explore new filings, reported insider transactions and company relationships.

Open company research ↗

Latest selected filing: Form 10-Q (quarterly report) · 2026-08-05

Annual financials

Annual flows and balances are grouped by their actual period end. Select a figure to open its SEC filing. n/a means a matching observation is unavailable. Free cash flow is operating cash flow minus capital expenditures, and EBITDA is operating income plus depreciation and amortization, for the same period, computed by TickerFacts.

The first column covers the twelve months to 2026-06-27 from the latest quarterly report: flows are the last fiscal year plus this year to date minus the same months a year earlier, and balances are as of that date. Per-share figures are annual only.

Period endedTTM to
2026-06-27		2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-31
Revenue$581.85M$568.09M$573.28M$512.35M$512.12M$430.90M$321.16M$340.14M
Cost of Revenue$182.40M$179.93M$185.05M$184.15M$181.04M$128.19M$87.64M$90.94M
Gross Profit$399.45M$388.16M$388.23M$328.19M$331.08M$302.71M$233.52M$249.21M
R&D Expense$11.57M$12.11M$13.95M$13.45M$23.85M$19.04M$11.20M$11.05M
Operating Income$58.28M$53.98M-$15.20M-$81.72M-$167.23M$12.06M$21.24M$31.19M
Depreciation & Amortization$45.25M$47.01M$49.55M$57.37M$55.40M$34.88M$28.64M$30.32M
EBITDA$103.53M$100.99M$34.36M-$24.36M-$111.84M$46.94M$49.88M$61.51M
Net Income$54.46M$22.73M-$36.12M-$156.23M-$158.70M$19.38M$16.41M$6.85M
EPS (Diluted)n/a$0.33-$0.56-$2.49-$2.59-$0.15n/an/a
Total Assets$673.35M$683.56M$727.96M$810.91M$1.37B$1.23B$494.47Mn/a
Total Liabilities$395.93M$455.11M$542.35M$589.79M$960.43M$618.21M$350.31Mn/a
Long-Term Debtn/an/an/an/an/a$357.68Mn/an/a
Shareholders' Equity$228.31M$184.10M$147.94M$173.59M$325.24M$458.92Mn/an/a
Cash & Equivalents$29.46M$51.24M$41.58M$36.96M$30.19M$43.93M$86.84Mn/a
Operating Cash Flow$96.87M$74.67M$38.80M$15.34M-$13.54M$22.99M$71.80M$40.71M
Capital Expenditures$2.59M$2.56M$1.01M$7.36M$1.48M$13.52M$16.58M$2.34M
Free Cash Flow$94.29M$72.11M$37.79M$7.98M-$15.02M$9.47M$55.22M$38.37M
Weighted Average Diluted Sharesn/a68.91M64.55M62.65M61.39M45.47Mn/an/a
EPS (Basic)n/a$0.34-$0.56-$2.49-$2.59-$0.15n/an/a

Price chart

Chart and quotes by TradingView. Exchange coverage and delays vary.

Open chart on TradingView